• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    'Oregon's First-In-Nation Psilocybin Industry Is Struggling To Find Paying Customers A Year After Launching' - Marijuana Moment

    6/12/24 2:07:09 PM ET
    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CMPS alert in real time by email

    https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/

    "Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated."

    By Grant Stringer, Oregon Capital Chronicle

    A year in, Oregon's experiment with the first regulated psilocybin mushroom market in the world is short on customers.

    To attract them, advocates say the industry needs to get the word out about its benefits.

    "We think everybody knows that psychedelics can help them because we're in this little bubble. But 99 percent of people have no idea what they could get out of a journey," said Heidi Venture, founder of a Hood River mushroom center, Vital Reset, where customers undergo supervised "trips" on psilocybin, the psychedelic compound in magic mushrooms.

    She was among about 100 local psilocybin entrepreneurs who attended a recent industry conference in Portland. Attendees included business owners like Venture who run state-licensed centers where customers can trip on mushrooms, and trained guides, known as facilitators, who accompany them on the hours-long journey.

    The conference was hosted by the Psilocybin Assisted Therapy Association, a nonprofit that's trying to raise awareness of the health and spiritual benefits detailed in studies on the supervised use of psychedelics like psilocybin.

    Panelists recalled a year of challenges, red tape and waning interest in guided mushroom trips under Oregon's pioneering legal model, but also life-changing experiences for clients. They pledged to share information and lobby lawmakers for regulatory improvements.

    A majority of Oregon voters in 2020 approved Measure 109, which directed the Oregon Health Authority to create a legal system for offering psilocybin. Unlike marijuana, customers can only buy and use psilocybin mushrooms under the watchful eye of a state-licensed facilitator and in a service center like Vital Reset. Prices usually range between $800 and $2,500 for a trip and two therapeutic sessions with a facilitator—although advocates say discounts are often available. Activists in other states are watching Oregon's experiment closely, including in Colorado, which is debuting a more relaxed system. Like Oregon, that state will license centers and facilitators but has also decriminalized the use and sharing of psilocybin and other psychedelics.

    When Oregon's first psilocybin center opened in Eugene in June 2023, it was the first in the nation to offer access to the drug in a licensed setting. The drug is still illegal by federal standards, categorized as a Schedule I substance, meaning that it has no accepted medical use and a high potential for abuse.

    To date, roughly 3,500 clients have taken a supervised trip in one of Oregon's 25 psilocybin centers.

    The nonprofit Healing Advocacy Fund, which advocates for psilocybin policy and supports entrepreneurs, estimates that number to increase to about 7,000 by the end of the year. That's lower than expected by some observers, who predicted a surge of interest in the nation's first legal opportunity to use a psychedelic drug.

    ‘It's going to get oversaturated'

    Oregon has 25 licensed centers, but not all of them have made it. In March, The Journey service center in Portland became the first to fold for a lack of customers.

    "Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated," said Tori Armbrust, owner of Satori Farms PDX. Armbrust grows psilocybin mushrooms and sells them to about half of the service centers in the state.

    She said competition will intensify next year, when out-of-state business interests can begin launching their own psilocybin ventures in Oregon.

    "Overall, marketing seems to be a big challenge. But places are doing well, and there's product going out to a lot of people," Armbrust said.

    Courtney Campbell, founder of the center Chariot in Northwest Portland, recently told a Capital Chronicle reporter that a steady stream of customers has kept his business afloat, but not lucrative.

    Oregon has also seen a spike in the number of training programs, which are pumping out hundreds of facilitators. Coeli Dwivedi, owner of the Entheogen Institute, has only been able to give herself one paycheck despite graduating about 70 students in the last year.

    "I'm looking forward to having a real salary as well," she said in an interview.

    Grassroots advertising

    Venture, who owns Vital Reset in Hood River, is trying to attract more customers. Like many centers, Vital Reset is offering discounts to people from underrepresented communities.

    However, she said she's hamstrung by strict rules on online advertisements for psilocybin services. According to the Healing Advocacy Fund, magic mushroom businesses must prove that their advertisements aren't reaching too many children or consumers under 21 years old. Plus, Venture and others believe that social media companies subtly suppress content related to psilocybin mushrooms. So Venture is relying on word-of-mouth and open houses to bring in business. She recently spoke about her business to members of a local Lions Club.

    Facilitators also say they are navigating a competitive market. About 325 facilitators have obtained a state license so far. Many have found that there are limited opportunities to work in service centers. It's common for more experienced facilitators to find their own clients and work underground, illegally supervising psilocybin trips at homes and in Airbnbs.

    Marlin Hofer, a facilitator at Brain Brew PDX and an instructor, said he carries a stack of business cards with him wherever he goes to raise awareness among the public.

    Matthew Wissler, another facilitator, said he would provide his services almost for free to certain low-income customers, such as those receiving food assistance, but he hasn't been able to find any who fit the bill. Initially, Oregon's model attracted wealthy tourists and people seeking treatment from other states and countries.

    While some facilitators are struggling to find work, some have found the work very lucrative, according to interviews with 10 facilitators.

    ‘Stay positive'

    Despite the business challenges, Oregon's psychedelic entrepreneurs are often floored by the positive impact felt by customers who use psilocybin, particularly people with treatment-resistant depression, addiction and trauma.

    "If we just hang in there, stay positive, it will evolve into something we can all be proud of," said Mary Nielsen, owner of Brain Brew PDX in Beaverton.

    To keep service centers financially sustainable, Armbrust suggested that the Oregon Health Authority limit the number of licenses it approves.

    Jesse Sweet, an Oregon Health Authority policy analyst, said the agency doesn't have that authority. The agency is kicking off another round of rules on a law requiring that centers collect certain data on their customers and will seek public input this year. Its new rules could tweak the current regulations, and lawmakers are expected to revisit the issue perhaps next year.

    Get the next $CMPS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPS
    $CYBN
    $DRUG
    $ENVB

    CompanyDatePrice TargetRatingAnalyst
    COMPASS Pathways Plc
    $CMPS
    12/10/2025$15.00Perform → Outperform
    Oppenheimer
    Mind Medicine (MindMed) Inc.
    $MNMD
    10/13/2025$28.00Buy
    Needham
    Bright Minds Biosciences Inc.
    $DRUG
    9/8/2025$72.00Buy
    BTIG Research
    Mind Medicine (MindMed) Inc.
    $MNMD
    8/4/2025$25.00Outperform
    Oppenheimer
    COMPASS Pathways Plc
    $CMPS
    6/23/2025$11.00 → $6.00Outperform → In-line
    Evercore ISI
    Bright Minds Biosciences Inc.
    $DRUG
    5/13/2025Buy
    TD Cowen
    Bright Minds Biosciences Inc.
    $DRUG
    5/7/2025$80.00Buy
    Chardan Capital Markets
    Cybin Inc.
    $CYBN
    3/13/2025$35.00Buy
    Guggenheim
    More analyst ratings

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    SEC Filings

    View All

    SEC Form S-8 filed by COMPASS Pathways Plc

    S-8 - COMPASS Pathways plc (0001816590) (Filer)

    3/24/26 4:47:18 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by COMPASS Pathways Plc

    S-8 - COMPASS Pathways plc (0001816590) (Filer)

    3/24/26 4:44:00 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by COMPASS Pathways Plc

    10-K - COMPASS Pathways plc (0001816590) (Filer)

    3/24/26 7:30:27 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights

    COMP360 is the first classic psychedelic1 to consistently achieve a highly statistically significant result and clinically meaningful effect in treatment resistant depression (TRD), with a generally well-tolerated and safe profile Across three large trials in TRD, including two positive Phase 3 studies, COMP360's differentiated profile is redefining rapidity and durability for TRD patients and demonstrating a consistent level of clinical effect that has never been achieved before Compass will meet with the FDA to confirm alignment on a rolling submission and review, and expects to complete the NDA submission in Q4 Compass is rapidly advancing commercial readiness plans and expects

    3/24/26 7:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Enveric Biosciences Announces Registration of Five Trademarks

    Canadian Trademark Office Issues House Marks to Enveric Biosciences, Inc. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the Canadian Intellectual Property Office has registered five of the Company's trademarks, including its house marks, Enveric and Enveric Biosciences. "The registration of a Company's house marks, such as our marks Enveric and Enveric Biosciences, is an important intellectual property milestone supporting our branding strategies for our future products. We thank the Canadian Intellectual Property

    3/18/26 8:00:00 AM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Compass Pathways to Present at Stifel 2026 Virtual CNS Forum on March 18, 2026

    Compass Pathways plc (NASDAQ:CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Stifel 2026 Virtual CNS Forum, from March 17-18, 2026, and will participate in a fireside chat on March 18, 2026, at 10:30am ET. A live audio webcast of this event will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (NASDAQ:CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental

    3/12/26 6:30:00 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    COMPASS Pathways upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded COMPASS Pathways from Perform to Outperform and set a new price target of $15.00

    12/10/25 8:10:44 AM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham initiated coverage on MindMed with a new price target

    Needham initiated coverage of MindMed with a rating of Buy and set a new price target of $28.00

    10/13/25 8:54:29 AM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    BTIG Research initiated coverage on Bright Minds Biosciences with a new price target

    BTIG Research initiated coverage of Bright Minds Biosciences with a rating of Buy and set a new price target of $72.00

    9/8/25 8:48:58 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nath Kabir covered exercise/tax liability with 13,131 units of Ordinary Shares, decreasing direct ownership by 6% to 191,990 units (SEC Form 4)

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    3/13/26 5:04:54 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Loxam Teri covered exercise/tax liability with 1,781 units of Ordinary Shares, decreasing direct ownership by 2% to 77,002 units (SEC Form 4)

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    3/13/26 5:03:11 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Loxam Teri covered exercise/tax liability with 4,467 units of Ordinary Shares, decreasing direct ownership by 5% to 78,783 units (SEC Form 4)

    4 - COMPASS Pathways plc (0001816590) (Issuer)

    3/3/26 7:58:25 PM ET
    $CMPS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gryska David W bought $17,925 worth of shares (2,500 units at $7.17), increasing direct ownership by 14% to 19,851 units (SEC Form 4)

    4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)

    12/5/24 4:30:05 PM ET
    $MNMD
    Medicinal Chemicals and Botanical Products
    Health Care

    Large owner Cormorant Asset Management, Lp bought $3,999,983 worth of shares (184,331 units at $21.70) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    11/6/24 4:20:48 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Cormorant Asset Management, Lp bought $3,234,387 worth of shares (422,591 units at $7.65) (SEC Form 4)

    4 - BRIGHT MINDS BIOSCIENCES INC. (0001827401) (Issuer)

    10/17/24 5:11:29 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Seelos Therapeutics Inc.

    SC 13G/A - SEELOS THERAPEUTICS, INC. (0001017491) (Subject)

    12/4/24 1:29:12 PM ET
    $SEEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cybin Inc.

    SC 13G - CYBIN INC. (0001833141) (Subject)

    12/3/24 5:23:26 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cybin Inc.

    SC 13G/A - CYBIN INC. (0001833141) (Subject)

    11/14/24 7:51:22 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Financials

    Live finance-specific insights

    View All

    Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

    BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep durationCompany has initiated preparations for global registrational trials in both DEE and Absence Seizure patientsBright Minds to hold conference call and live webcast at 8AM ET today NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical

    1/6/26 7:16:55 AM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026

    – Conference Call and Live Webcast at 8AM ET – NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Minds" or the "Company"), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy. Webcast Information The Bright Minds virtual event will be webcast live and a replay will be available after th

    1/5/26 4:30:00 PM ET
    $DRUG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025

    - Company to host conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a breakthrough Phase 3 clinical stage neuropsychiatry company committed to revolutionizing mental healthcare through proprietary drug discovery platforms and innovative delivery systems, today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 13, 2025, to provide a business update and report financial results for its second quarter ended September 30, 2025. CONFERENCE CALL DETAILS: Dial-in: 800-245-3047 (U.S. toll free) or 203-518-9765 (International) Conference ID: CYBN1113 Webcast: R

    11/6/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CMPS
    $CYBN
    $DRUG
    $ENVB
    Leadership Updates

    Live Leadership Updates

    View All

    Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

    Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) , a clinical-stage breakthrough pharmaceutical company committed to revolutionizing mental healthcare by developing innovative next-generation treatment options, today announced that it will voluntarily transfer its U.S. stock exchange listing to the Nasdaq Global Market ("Nasdaq") from the NYSE American LLC ("NYSE American"). The Company expects that its common shares will cease trading on the NYSE American at market close on January 4, 2026 and commence trading on Nasdaq at market open on January 5, 2026. Concurrent with the commencement of trading on Nasdaq, the Company will no longer trade under the ticker symbol "CYBN" and instead will trade under

    12/18/25 7:30:00 AM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ENvue Medical Appoints Veteran Healthcare-Industry Executive, David Johnson, as Chairman

    ENvue Medical, Inc. (NASDAQ:FEED) ("ENvue" or the "Company"), a medical technology company specializing in non-invasive therapeutic systems, today announced the appointment of David Johnson as Chairman of the Board. Mr. Johnson will work alongside CEO, Doron Besser, and the existing leadership team. David Johnson, newly appointed Chairman of ENvue, stated, "We believe ENvue is at the forefront of advanced feeding-tube placement technology, which has been validated in the market and extensively used in the clinic across 38 hospitals in the US. In my opinion, the Company's unique feeding tube placement system that utilizes advanced methods of navigation, integrated sensors and body mapping h

    12/15/25 9:00:00 AM ET
    $ENVB
    $FEED
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Cybin Announces Results of Annual Meeting of Shareholders

    Cybin Inc. (NYSE:CYBN) (Cboe CA: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual meeting of shareholders held on August 18, 2025 (the "Meeting"). There were 90 shareholders represented in person or by proxy at the Meeting holding 11,264,212 common shares, representing 48.92% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are set out below:

    8/18/25 5:30:00 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care